Paradoxical Reaction to Golimumab: Tumor Necrosis Factor α Inhibitor Inducing Psoriasis Pustulosa

• Published in: Case reports in dermatology Vol. 5; no. 3; pp. 326 - 331
• Main Authors: Soto Lopes, Marien Siqueira, Trope, Beatriz Moritz, Rochedo Rodriguez, Maria Paula Rua, Grynszpan, Rachel Lima, Cuzzi, Tullia, Ramos-E-Silva, Marcia
• Format: Report
• Language: English
• Published: 01.01.2013
• ISSN: 1662-6567; 1662-6567
• DOI: 10.1159/000350930

IMPORTANCEGolimumab is a human monoclonal antibody, used for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Adverse reactions are increasing with this class of medication (tumor necrosis factor α inhibitors). OBSERVATIONSThe authors present a case of a female patient who presented with psoriasis pustulosa after the use of golimumab for rheumatoid arthritis. CONCLUSIONS AND RELEVANCEParadoxically, in this case, golimumab, which is used for psoriasis, induced the pustular form of this disease. We are observing an increasing number of patients who develop collateral effects with tumor necrosis factor α inhibitors, and the understanding of the mechanism of action and how these adverse reactions occur may contribute to avoid these sometimes severe situations.